MARLBOROUGH, Mass.,
Jan. 31, 2017 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) has completed the divestiture of its
blood screening business to long-time commercial partner, Grifols
(MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) for a purchase price of
$1.85 billion in cash, the Company
announced today.
"Completing the divestiture of our blood screening business will
strengthen our efforts to build a sustainable growth company by
accelerating top- and bottom-line growth rates, while significantly
increasing financial flexibility," said Steve MacMillan, the Company's Chairman,
President and Chief Executive Officer. "We are immensely
proud of the contributions we have made to global blood safety over
nearly 20 years, and wish our former employees and partner much
continued success in the field."
Hologic intends to discuss the financial effects of the
transaction tomorrow, when it releases its quarterly financial
results and provides updated financial guidance.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier
of premium diagnostic products, medical imaging systems and
surgical products. The Company's core business units focus on
diagnostics, breast health, GYN surgical, and skeletal
health. With a unified suite of technologies and a robust
research and development program, Hologic is dedicated to The
Science of Sure. For more information on Hologic, visit
www.hologic.com.
Hologic, The Science of Sure, and associated logos are
trademarks and/or registered trademarks of Hologic, Inc. and/or its
subsidiaries in the United States
and/or other countries.
Forward-Looking Statements
This news release contains forward-looking information that
involves risks and uncertainties, including statements about the
Company's plans, objectives, expectations and intentions.
Such statements include, without limitation: financial or other
information based upon or otherwise incorporating judgments or
estimates relating to future performance, events or expectations;
the Company's strategies, positioning, resources, capabilities, and
expectations for future performance; and the Company's outlook and
financial and other guidance. These forward-looking
statements are based upon assumptions made by the Company as of
this date and are subject to known and unknown risks and
uncertainties that could cause actual results to differ materially
from those anticipated.
Risks and uncertainties that could adversely affect the
Company's business and prospects, and otherwise cause actual
results to differ materially from those anticipated, include
without limitation: the ability of the Company to realize
anticipated benefits of future strategic alliances; the risks of
conducting business internationally; the Company's ability to
predict accurately the demand for its products and products under
development, and to develop strategies to address its markets
successfully; the early stage of market development for certain of
the Company's products; technical innovations that could render
products marketed or under development by the Company obsolete; and
competition.
The risks included above are not exhaustive. Other factors
that could adversely affect the Company's business and prospects
are described in the filings made by the Company with the
SEC. The Company expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
such statements presented herein to reflect any change in
expectations or any change in events, conditions or circumstances
on which any such statements are based.
Contact
Michael Watts
Vice President, Investor Relations and Corporate Communications
(858) 410-8588
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/hologic-completes-divestiture-of-blood-screening-business-300399746.html
SOURCE Hologic, Inc.